RAMM Pharma Corp.
RAMM
CNSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -53.33% | -42.32% | -24.89% | -17.66% | -13.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.33% | -42.32% | -24.89% | -17.66% | -13.41% |
| Cost of Revenue | -54.48% | -32.56% | -5.07% | -28.58% | -42.08% |
| Gross Profit | -51.40% | -56.99% | -53.59% | 60.80% | 414.75% |
| SG&A Expenses | -41.35% | -48.87% | -47.63% | 4.39% | 13.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -37.34% | -35.69% | -34.79% | -12.26% | -16.19% |
| Total Operating Expenses | -44.34% | -45.26% | -38.77% | -7.25% | -7.62% |
| Operating Income | 39.09% | 46.88% | 46.14% | 0.44% | 3.87% |
| Income Before Tax | 37.03% | 44.86% | 47.19% | -47.71% | -51.76% |
| Income Tax Expenses | -15.38% | 229.53% | 84.75% | 28.17% | 28.17% |
| Earnings from Continuing Operations | 37.01% | 43.92% | 47.12% | -47.68% | -51.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.01% | 43.92% | 47.12% | -47.68% | -51.73% |
| EBIT | 39.09% | 46.88% | 46.14% | 0.44% | 3.87% |
| EBITDA | 38.14% | 48.02% | 48.28% | -7.59% | -1.15% |
| EPS Basic | 36.92% | 43.88% | 47.14% | -47.45% | -51.63% |
| Normalized Basic EPS | 33.33% | 39.19% | 41.90% | 13.60% | 8.03% |
| EPS Diluted | 36.92% | 43.88% | 47.14% | -47.45% | -51.63% |
| Normalized Diluted EPS | 33.33% | 39.19% | 41.90% | 13.60% | 8.03% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.01% | -0.26% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.01% | -0.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |